Study of a New Blood Test Using Multiplex Quantitative PCR to Improve Diagnosis of Alveolar and Cystic Echinococcosis in Adults

What this Trial Is About

Echinococcosis is a serious parasitic disease caused by tapeworm larvae, leading to alveolar or cystic echinococcosis. Treatment often involves surgery or benzimidazole drugs like albendazole, which slows parasite growth but doesnt kill it, requiring lifelong use and regular monitoring. Diagnosis uses imaging and blood tests, but sensitivity varies, especially in patients with weakened immune systems. Researchers are evaluating a new multiplex quantitative PCR QPCR-Echino test to detect DNA from the parasites in blood and tissues, aiming to improve diagnosis and monitoring, particularly in immunocompromised patients who face delays in diagnosis. The study involves collecting blood samples to perform the new QPCR-Echino test at the start and after one year. This test targets DNA from Echinococcus multilocularis and Echinococcus granulosus species found in Europe. The goal is to assess how well this new technique performs compared to current methods for diagnosing echinococcosis. Participants will provide blood samples upon joining the trial and again after one year. Researchers will analyze these samples using the QPCR-Echino method to evaluate diagnostic accuracy and effectiveness over time. The study will measure performance indicators of this diagnostic technique within one year, helping to improve detection and management of echinococcosis. The total participation time includes initial and one-year follow-up blood testing.

Evaluation of a New Multiplex Quantitative PCR Technique for the Diagnosis of Echinococcosis